International consensus statement on the use of disease-modifying agents in multiple sclerosis

M. S. Freedman, L. D. Blumhardt, B. Brochet, G. Comi, J. H. Noseworthy, M. Sandberg-Wollheim, P. Soelberg Sørensen

Research output: Contribution to journalArticlepeer-review


Objective: To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit. Methods: An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment. Results: A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop. Conclusions: Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalMultiple Sclerosis Journal
Issue number1
Publication statusPublished - 2002


  • Consensus
  • Glatiramer acetate
  • Interferon beta
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'International consensus statement on the use of disease-modifying agents in multiple sclerosis'. Together they form a unique fingerprint.

Cite this